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Transfusion-related acute lung injury (TRALI) is a serious clinical
syndrome that is temporally associated with the transfusion of
plasma-containing blood components. The syndrome typically
occurs within 6 hours of transfusion. Approximately 80 percent of
cases will resolve within 96 hours with supportive care. The
syndrome has been associated with antibodies toWBC antigens and
generation of biologically active mediators in stored cellular blood
components. Appropriate laboratory investigation of TRALI can be
crucial in confirmation of the clinical diagnosis, as well as in
decisions regarding donor management. Immunohematology
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Transfusion-related acute lung injury (TRALI) is a
syndrome that is clinically indistinguishable from acute
respiratory distress syndrome (ARDS).1 TRALI can
occur within 6 hours of transfusion, but usually occurs
within 1 to 2 hours.2 Symptoms and signs can include
shortness of breath, difficulty breathing, hypoxia, fever,
hypotension, and hypertension preceding hypo-
tension.3 All plasma-containing blood components,
including whole blood, packed RBCs, fresh frozen
plasma,2 platelet concentrates,4,5 apheresis platelets,6,7
granulocytes,8 cryoprecipitate,9 allogeneic bone
marrow,10 and IVIG,11 have been associated with TRALI.
Although the pathogenesis of TRALI is not completely
understood, it has been associated with antibodies to
WBCs2,7,12 and with the infusion of biologically active
mediators in stored cellular blood components.13,14
Clinical Syndrome
In most cases of TRALI, clinical symptoms begin
within 1 to 2 hours of completion of the transfusion.
Symptoms can begin up to 6 hours after transfusion.2
There are rare case reports of mild symptoms
beginning within 6 hours of transfusion with rapid
resolution of symptoms and reappearance of more
severe symptoms about 24 hours after transfusion.15
Signs and symptoms include fever, dyspnea,
hypotension, hypertension followed by hypotension,
and noncardiogenic pulmonary edema. Although any
of these signs and symptoms can be seen in TRALI, not
all of them will be present in every case.
Patients who are intubated, at the time of the
reaction or shortly after the reaction begins, are
described as producing copious quantities of frothy
fluid from the endotracheal tube.16–19 The frothy quality
of this fluid is secondary to its high protein content.
The ratio of protein concentration in edema fluid to
protein concentration in the blood in patients with
noncardiogenic pulmonary edema is typically > 0.7,
while the ratio is usually < 0.5 in cardiogenic
pulmonary edema.20 Yost et al.21 analyzed the protein
content of pulmonary edema fluid in seven cases of
TRALI that occurred after liver transplantation. In all
seven cases, the ratio of protein in the pulmonary
edema fluid to protein in the blood was > 0.7.
The chest X-ray becomes abnormal at the time of
the reaction. In recumbent patients, a patchy infiltrate
may first appear in the dependent areas of the lungs.
The infiltrate rapidly progresses to bilateral“white out.”
This pattern is caused by pulmonary edema and is
indistinguishable from the pattern seen in ARDS.
In approximately 80 percent of cases, the
symptoms completely resolve within 96 hours of
transfusion.2 Once the symptoms resolve, there are no
chronic manifestations of TRALI. Fatal reactions occur
in 5 percent to 10 percent of cases. Fatalities can occur






course of mechanical ventilation. In the remaining
cases, patients fully recover after intensive support and
mechanical ventilation.
Differential diagnosis
The most important factor in the differential
diagnosis of TRALI is to determine the nature of the
pulmonary edema. The edema in TRALI is noncardio-
genic in nature. Other forms of pulmonary edema
include cardiogenic and volume overload. TRALI, or
noncardiogenic pulmonary edema, can easily be
confused with these other two types of pulmonary
edema, particularly in critically ill patients and those
who have received large volumes of intravenous fluids,
including blood components.
Volume overload pulmonary edema is associated
with other signs of fluid overload, including jugular
venous distension and increased blood pressure.
Cardiogenic pulmonary edema is associated with signs
and symptoms of heart failure, including gallops,
murmurs, or possibly evidence of myocardial
ischemia/infarction on electrocardiogram. Additionally,
laboratory tests for myocardial infarction and heart
failure, including creatine kinase, troponin, and B-type
natriuretic peptide,can aid in the differential diagnosis.
All of these tests should be within normal limits in
TRALI.
Incidence
TRALI is one of the most common causes of
transfusion-related mortality. It has been reported as
the third leading cause of transfusion-related mortality
in the United States22 and the most common cause in
the United Kingdom.23 An accurate estimate of the
incidence of TRALI has been difficult to establish. Most
of the published estimates of the incidence of TRALI
are based upon calculating the number of cases of
TRALI that occur at a specific institution over a period
of time, compared to the number of components or
patients transfused during the same period. These
studies have led to estimates of one case of TRALI per
5000 components transfused2 and one case per 2400
patients transfused.24
Although these studies give an estimate of the
incidence of TRALI, there is a growing appreciation that
TRALI may be underdiagnosed and underreported.25 A
recent retrospective study examined the medical
records of the recipients of blood components donated
by a female donor who was implicated in a fatal case of
TRALI.25 The implicated donor had a strong antibody to
the granulocyte 5b antigen (HNA-3a) and had donated
apheresis plasma (600 mL) in a frequent plasma
donation program. The medical records of 36 recipients
of this donor’s plasma were reviewed by transfusion
service medical directors for indications of TRALI
associated with transfusion of the blood components.
Reactions were classified as mild to moderate or severe.
Severe reactions were defined as acute onset of
pulmonary edema, or need for mechanical ventilation,
associated with transfusion. Mild to moderate reactions
were defined as dyspnea, and/or oxygen desaturation
without overt clinical evidence of pulmonary edema,
associated with transfusion. Eight severe reactions were
identified in eight recipients, while seven mild to
moderate reactions were identified in six recipients.
Only two of the eight severe reactions were reported to
the transfusion service, while five of the seven mild to
moderate reactions were reported to the transfusion
service. Only two of the reactions (one mild to
moderate and one severe) were reported to the blood
collection facility. The two reactions reported to the
blood collection facility were the fatal reaction that
prompted the look-back and a mild to moderate
reaction that occurred at the same institution during
the initial investigation of the fatality. The observation
that mild to moderate TRALI reactions were reported to
the transfusion service more frequently than severe
reactions may be explained by the fact that the mild to
moderate manifestations of TRALI can clinically
resemble febrile nonhemolytic transfusion reactions
(FNHTR) that are routinely reported to the transfusion
service.
This “look-back” study emphasizes the importance
of clinical recognition of TRALI. Pulmonary symptoms
that occur within 6 hours of transfusion should be
reported to the transfusion service for further
investigation, particularly when there is no other
clinical explanation for the symptoms. After
investigation by the transfusion service, probable cases
of TRALI should be referred to the blood collection
facility for donor testing and possible deferral of
implicated donors, depending upon the results of the
laboratory investigation.
The Antibody Hypothesis for TRALI
The first published case report of what was most
likely TRALI was reported in 1951.26 During the next
30 years there were several case reports of
noncardiogenic pulmonary edema associated with
transfusion.8,16,27–34 These case reports attribute the
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pulmonary edema to several different causes, including
incompatibility of an undetermined nature,28 human
leukocyte antigen (HLA) incompatibility,32 non-HLA
leukoagglutinins,30 undefined granulocyte leukoag-
glutinins,34 and severe allergic pulmonary edema.8,16,31
Antibodies to HLA Class I and granulocyte antigens
were associated with TRALI by Popovsky et al.2,17 In a
series of 36 patients, granulocyte antibodies were
identified in the serum of at least one implicated donor
in 89 percent of cases. The presence of lymphocyte
antibodies was determined, by reverse lymphocyto-
toxic crossmatch, in the serum of at least one
implicated donor, in 26 of the 36 cases (72%).
Specificity of the HLA antibodies was further
characterized by lymphocyte panel testing in 17 of the
26 cases with HLA antibody. A clear HLA specificity
was determined in 11 of the 17 cases (65%). The
specificity of the antibody was determined to
correspond to at least one of the recipient’s HLA
antigens in 10 of the 17 cases.
Many of the early case reports of TRALI report the
presence of granulocyte or HLA antibodies based upon
a positive reverse granulocyte or lymphocyte cross-
match. The results of these tests can be misleading
because of the presence of other antigen systems on
these cells. This has the potential to result in incorrect
interpretation of crossmatch results. An example of
this is the granulocyte 5b antigen. Since this antigen is
present on lymphocytes in addition to granulocytes,35,36
a positive reverse lymphocyte crossmatch may lead to
the misinterpretation that lymphocyte or HLA
antibodies are responsible for the TRALI reaction.
The technologies available to identify HLA
antibodies have dramatically evolved in the last 10 years
with the availability of solid phase assays such as flow
cytometry and ELISA in most histocompatibility
laboratories. Because these technologies are based
upon isolation and adherence of HLA antigens to a latex
bead (flow cytometry) or solid surface (ELISA), they are
more specific for detection of HLA antibodies than tests
based upon lymphocytotoxicity. Additionally, these
tests do not depend upon the ability of the antibody to
activate complement and cause cellular lysis.
A recent study by Kopko et al.7 investigated 16
cases of TRALI. This study examined donor-recipient
pairs involved in TRALI reactions. Donors were tested
for HLA and monocyte antibodies by flow cytometry,
HLA antibodies via a lymphocytotoxic panel, and
granulocyte antibodies by granulocyte agglutination
(GA) and granulocyte immunofluorescence (GIF).
Recipients were typed for HLA Class I and II antigens
in all cases. If the donor(s) did not possess HLA or
granulocyte antibodies, the recipient was evaluated for
antibodies to HLA Class I and II antigens. In 14 of the
16 cases (87.5%), a correlation was identified between
antibody present in the donor or the recipient and
antigen in the other member of the donor-recipient
pair. The identity of the antibody involved in these
cases was HLA Class I (4), HLA Class II (5), HLA Class I
and II (2), granulocyte (1), and monocyte (2). In the
two cases where antibody was not identified, recipient
samples were not available for antibody testing. Several
recent case reports support the association of HLA
Class II antibodies with TRALI.12,37–40
Six of the 16 TRALI cases described above were
further investigated for the ability of the sera
containing antibody from one member of the donor-
recipient pair to activate monocytes in the other
member of the pair. The fraction of cells expressing the
cytokines interleukin 1β (IL-1β) and tumor necrosis
factor α (TNF-α) or tissue factor were measured as an
indicator of monocyte activation. Expression of the
two cytokines and tissue factor were measured after
exposure to autologous serum, control serum (serum
from the donor of another blood component the
patient received or ABO-matched control serum), or
serum involved in the TRALI reaction. There was
significantly increased expression of all three factors in
the monocytes exposed to TRALI serum compared to
autologous serum and control serum (p < 0.05).
TRALI has been reproduced in an ex vivo animal
lung model.41 In this model, pulmonary edema is
produced after a latent period of 3 to 6 hours when
rabbit lungs are perfused with 5b-positive
granulocytes, antibody to granulocyte 5b, and rabbit
plasma as a source of complement. If any of these
three components is absent, pulmonary edema does
not occur. The pulmonary edema produced in these
experiments was noncardiogenic in nature. This was
demonstrated by monitoring of pulmonary artery
pressure, which displayed only a transient and
moderate increase. Increased pulmonary vascular
permeability was the cause of the edema.
In the antibody-mediated model of TRALI, antibody-
coated leukocytes localize to the pulmonary micro-
vasculature. Cytokine release by these leukocytes is
thought to damage the vascular endothelium. Damage
to the endothelium of the pulmonary microvasculature
is thought to cause increased vascular permeability.
This results in leakage of protein-rich fluid into the
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pulmonary alveoli and results in pulmonary edema.
This theory is supported by the findings of McCullough
et al.,42 who have demonstrated that 111Indium-labeled
granulocytes localize to the pulmonary microvascula-
ture when transfused to a recipient with antibodies
directed against the granulocytes.
A recent case report suggests that interaction of
antibody with leukocytes may not be necessary for
TRALI to occur.43 In this case, a 34-year-old woman
who received two units of packed RBCs approximately
10 weeks after undergoing a lung transplant
experienced a TRALI reaction. Pulmonary edema was
present in the transplanted, but not in the native, lung.
Antibodies to HLA-B44 were identified in the donor of
the second unit of packed RBCs. No leukocyte
antibodies were identified in the donor of the first unit
of packed RBCs. The transplanted lung possessed the
HLA-B antigen, while the patient did not. Since very
few WBCs of donor origin would be expected to be
present in the transplant recipient 10 weeks after
transplant, and the pulmonary endothelial cells would
be expected to be of donor origin, this case suggests
that TRALI may be initiated directly through antibody
interaction with endothelial cells.
The Biologically Active Mediator Model for
TRALI
Biologically active mediators in cellular blood
components, at or near the time of outdate, have been
associated with TRALI.13 In this theory of TRALI,
biologically active mediators or lipids accumulate
during storage of cellular blood products, including
packed RBCs and platelets. These agents enhance or
prime neutrophil NADPH Oxidase. In this model, two
events are required for a reaction to occur.44 In the first
event, biologically active mediators are generated
during physiologic stress. These stressors can include
events such as trauma, infection, recent surgery, and
massive transfusion. Generation of biologically active
compounds, related to stress, is hypothesized to
activate the pulmonary vascular endothelium and
prime neutrophils. These actions are thought to cause
sequestration of neutrophils within the pulmonary
microvasculature. The second event consists of the
infusion of biologically active mediators in a cellular
blood component.
This model of TRALI is supported by a
retrospective study performed by Silliman and
colleagues.14 The records of ten transfusion recipients
who experienced TRALI were assessed for the
presence of a“first event” that would have predisposed
them to developTRALI. A control group of ten patients
who experienced a febrile or urticarial reaction was
also assessed for the presence of a “first event”prior to
transfusion. All of the patients in the TRALI group had
an underlying clinical factor that could have
predisposed them to develop TRALI, while only two
patients in the control group had such underlying
clinical factors. Clinical factors thought to predispose
a patient to developing TRALI included infection,
cytokine administration, recent surgery, and massive
transfusion.
This mechanism of TRALI has also been reproduced
in an ex vivo animal lung model.45 In this study,rat lungs
were first pretreated with lipopolysaccharide (LPS) to
simulate sepsis. The lungs were perfused with one of
the following solutions:buffered salt solution,5% human
plasma in saline, 5% supernatant from day 0 or day 5
platelets (both whole blood–derived and apheresis
platelets), or lipid extracts from day 0 or day 5 platelets.
Pulmonary edema (lung weight) and leukotriene B4
levels (a measure of lung injury) were measured. Plasma
from day 5 apheresis or whole blood–derived platelets,
as well as lipid extracts from these components, caused
increased pulmonary edema (p < 0.05) when the lungs
were first treated with LPS compared to saline
pretreated and saline perfused lungs. Pulmonary edema
did not develop if the lungs were pretreated with saline
instead of LPS. Lungs perfused with supernatant or lipid
extract from day 0 whole blood–derived or apheresis
platelets did not develop pulmonary edema.
Leukotriene B4 levels were increased in the lung
perfusate (p < 0.05) only after pretreatment with LPS
and perfusion of the lungs with 5% supernatant from day
5 platelets. Leukotriene B4 levels were not measured
after treatment with lipid extracts. Prestorage
leukoreduction of platelets did not alter the pulmonary
edema that developed in these experiments. Pulmonary
artery pressure was monitored in these experiments to
ensure the edema was noncardiogenic in nature.
Significant, sustained increases in pulmonary artery
pressure were not observed.
Silliman et al.46 recently published a study of 90
TRALI reactions occurring during a 4-year period at a
single institution. The blood components implicated in
these reactions were platelet concentrates (72),
apheresis platelets (2), packed RBCs (15), and plasma
(1). The first 46 reactions were analyzed in a nested
case-control study. Patient and blood component data
were compared in these cases to a control group of
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225 recipients of platelet concentrates. TRALI was not
associated with patient age or gender, incompatibility
of patient-donor blood groups, number of previous
transfusions, or number and type of previous
transfusion reactions. TRALI was associated with a
diagnosis of hematologic malignancy (p < 0.0004) and
cardiac disease (p < 0.0006). TRALI was also associated
with increasing age of platelet concentrate transfused
(p = 0.014). Pretransfusion and posttransfusion
samples from the last 51 patients who experienced
TRALI were analyzed for the accumulation of
polymorphonuclear neutrophil leukocyte priming
activity. There was significantly more priming activity
(p < 0.05) in the posttransfusion samples compared to
pretransfusion samples and controls.
Pathophysiology of TRALI
Although two seemingly dissimilar mechanisms
have been associated with TRALI, it is possible that
both mechanisms may be involved in the reaction.
Activation of leukocytes with endothelial damage,
increased vascular permeability, and resultant
pulmonary edema are common to the antibody-
mediated model of TRALI and the biologically active
mediator model of TRALI. Additionally, look-back
studies have shown that the presence of antibody in a
donor is not sufficient to cause TRALI in all recipients,
even if the recipient possesses an antigen
corresponding to the infused antibody.25,47 These
studies suggest that two events may be needed for
TRALI to occur. Biologically active mediators have
been demonstrated in cellular blood components,
while they have not been routinely demonstrated in
FFP. Since FFP has frequently been implicated in
TRALI,7,18,31,48 biologically active mediators alone can’t
explain all cases of TRALI.
An important point to remember when
considering the two hypotheses for TRALI is that the
differences in transfusion practice around the country
and around the world may affect the findings in TRALI
investigations. Although the author’s institution has
reported identifying antibody in one member of the
donor-recipient pair in the majority of cases, those data
are possibly biased by our area’s transfusion practices.
Hospitals supplied by the author’s blood center have
exclusively received apheresis platelets for more than a
decade. For the last 7 years, the apheresis platelets
have been leukocyte reduced during the collection
process. Additionally, the overwhelming majority (>
98%) of RBCs collected within the last few years
have been prestorage leukoreduced. Therefore, if
biologically active mediators are associated with
nonleukoreduced platelet and RBC concentrates,46 it
would be unlikely that a case of TRALI due to these
substances would be found at the author’s center.
Clinical Investigation
The laboratory investigation of TRALI can be a
frustrating and costly task. Cases of TRALI are often
referred to the clinical laboratory with a large number
of implicated blood components. Additionally, the
laboratory is seldom provided data regarding when the
implicated blood components were transfused relative
to the reaction. Since most cases ofTRALI occur within
1 to 2 hours of transfusion, this information is essential
to the laboratory investigation of TRALI. Therefore, it is
important to obtain this detail prior to initiating
testing. This allows the laboratory to prioritize testing
of implicated donors. The use of a testing algorithm in
the laboratory investigation of TRALI can significantly
reduce the cost of working up a case.
It is strongly recommended that donor-recipient
pairs be investigated in TRALI cases. One of the most
important steps needed to accomplish a complete
laboratory investigation is to obtain the appropriate
samples from the recipient as soon as TRALI is
considered a possibility. If recipient samples for HLA
typing and antibody studies are not drawn early in the
investigation, they may not be available if they are
needed to correlate results in the recipient with results
from the donor(s).
A suggested testing algorithm is presented in
Table 1. Testing should begin with female donors of
blood components transfused within 2 hours of the
reaction. Since testing for HLA antibodies is more
readily available than testing for granulocyte
antibodies, and HLA antibodies have recently been
associated with TRALI more often than granulocyte
antibodies, testing can begin with HLA Class I and II
antibodies. If no HLA antibodies are detected, testing
for granulocyte antibodies should be performed. The
recipient should be HLA typed (Class I and II) to
determine whether antibodies identified in a donor
correspond to recipient antigens.
If female donors of blood components transfused
within 2 hours of the reaction are negative for HLA and
granulocyte antibodies, female donors of blood
components transfused within 6 hours of the reaction
should be tested for HLA antibodies, followed by
testing for granulocyte antibodies. If all female donors
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of blood components transfused within 6 hours of the
reaction are negative for HLA and granulocyte
antibodies, the recipient can be tested for these
antibodies. This step will allow diagnosis of the
approximately 10 to 15 percent of TRALI cases that are
associated with antibodies in the recipient. If the
transfusion recipient is at high risk of having leukocyte
antibodies, due to a history of pregnancy or
transfusion, it may be advisable to test the recipient for
antibodies earlier in the course of the workup,
particularly if the patient received a nonleukocyte
reduced cellular blood component (i.e., packed RBCs
or platelets).
If the recipient and the female donors of blood
components transfused within 6 hours of the reaction
are negative for HLA and granulocyte antibodies, male
donors of blood components transfused within 2 hours
of the reaction can be tested next. If the testing is still
negative,male donors of blood components transfused
within 6 hours of the reaction can be tested. At any
point in the TRALI investigation, if antibody is
identified in one member of the donor-recipient pair
and it corresponds to antigen in the other member of
the donor-recipient pair, further workup can be halted.
Currently, testing for monocyte antibodies and
biologically active mediators is not commercially
available. If testing for HLA and granulocyte antibodies
is negative in the donor(s) and recipient, testing for
these other factors associated with TRALI can be
obtained through research laboratories.
Treatment
Because TRALI occurs infrequently, there are no
clinical studies of appropriate treatment after a
reaction has occurred. The only treatments that can be
recommended are supportive care for the patient’s
symptoms, including oxygen support with or without
mechanical ventilation, and fluid administration. The
use of steroids for treatment of TRALI is anecdotal.
Therefore, no recommendation regarding steroid use
can be made.
One caution in the treatment of TRALI is the
avoidance of diuretics. There are several case reports
that describe worsening of the patient’s clinical
condition and even fatality following administration of
diuretics after a reaction.8,18 Since the pulmonary
edema associated with TRALI is noncardiogenic,
patients are not typically volume overloaded. The
patient may be hypovolemic due to the underlying
condition or secondary to the extravasation of fluid
into the lungs. Therefore, administration of diuretics
can lead to hypotension, decreased cardiac output, and
decreased pulmonary capillary wedge pressure.8,18
Donor Management Issues
One of the most important considerations
regarding TRALI is donor management. Several
different suggestions regarding donor management
have been published. These include deferring all
females from donating plasma for transfusion,49
Table 1 . Laboratory investigation of TRALI
Recipient samples and testing
1. When TRALI is first suspected, obtain serum/plasma and cellular
samples (citrate anticoagulant)
2. Obtain HLA Class I and II typing on cellular samples or freeze cells for
DNA for future testing
3. Freeze recipient serum/plasma sample for future testing (prereaction
and postreaction samples, if available)
4. Separate and freeze liquid portion of remaining contents of bag, if
available, for future testing
Donor testing—HLA and granulocyte
1. Obtain transfusion history including:
a. Unit number of transfused component(s)
b. Start/stop times of all components transfused
c. Time of first symptoms of reaction
d. Gender of donor of each of the components transfused within 6
hours of reaction symptoms
2. Test female donors of components transfused within 2 hours of
reaction for HLA Class I and II antibodies
a. If positive—correlate with recipient HLA typing (donor in step 4)
i. If correlation exists—stop
b. If negative—test donors (recipient in step 4) for granulocyte
antibodies
i. If positive—correlate with antigens in recipient (donor in
step 4)
1. If correlation exists—stop
ii. If negative—proceed to next step
3. Test female donors of components transfused within 6 hours of
reaction for HLA Class I and II antibodies (go to step 2a)
4. If recipient is at increased risk of having antibodies (multiparous or
recipient of an organ allograft or multiple transfusions) and received a
cellular blood component (go to step 2a)
5. Test male donor of components transfused within 2 hours of reaction
for HLA Class I and II antibodies (go to step 2a)
6. Test male donors of components transfused within 6 hours of reaction
for HLA Class I and II antibodies (go to step 2a)
7. Consider obtaining monocyte antibody testing (available through
research laboratories only)
Testing for biologically active mediators
Testing should be considered (available through research laboratories
only) if:
• Recipient received a cellular blood component with little plasma
content
• Reaction occurred after transfusion of an autologous blood
component
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deferring multiparous females from donating plasma
for transfusion,49 deferring multiparous females from
plasma donation unless their serum has been tested for
antibodies to leukocytes,50 and deferring donors
implicated in a TRALI case, if they have been found to
have antibody in their serum that corresponds to
antigen on the TRALI patient’s leukocytes.25,50 Each of
these donor management strategies would reduce the
risk of TRALI in transfusion recipients. However, none
of them would completely eliminate TRALI.
Deferring high-risk donors from donating plasma
components would not eliminate the risks associated
with the plasma in other blood components. A recent
retrospective study correlated the volume of plasma in
a blood component with the likelihood that a blood
component would be implicated in a TRALI case.51 If
the volume of plasma in a blood component correlates
to the risk of TRALI from a blood component, then
apheresis platelets would have a slightly greater risk of
causing TRALI than plasma derived from a
whole–blood donation. None of the deferral strategies
that exclude donors based upon gender or parity
include deferral from apheresis platelet donation.
Additionally, very small volumes of plasma have been
shown to cause TRALI.27 These deferral strategies
would not prevent cases of TRALI secondary to the
small volumes of plasma present in cryoprecipitate or
RBC and platelet concentrates.
None of the donor management strategies would
prevent cases of TRALI secondary to antibody in the
recipient. Finally, none of the strategies would address
the association of TRALI with biologically active lipids.
There are also obstacles to screening female or
multiparous donors for antibodies to leukocytes. In
order to screen for leukocyte antibodies, a test that
could be performed on a large number of donors in a
short period of time would be needed. Although
screening tests for HLA Class I and II antibodies using
flow cytometry or ELISA methodologies are currently
available commercially, there are no such tests available
for screening for antibodies to the granulocyte 5b
antigen. Since this antibody has recently been reported
in association with three fatal cases of TRALI,25,52
inclusion of a test for this antibody in a screening test
would be ideal.
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